Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls.

Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, Feikin DR, Groome MJ, Hajjeh RA, Johnson HL, Madhi SA, Mulholland K, O'Brien KL, Parashar UD, Patel MM, Rodrigues LC, Santosham M, Scott JA, Smith PG, Sommerfelt H, Tate JE, Victor JC, Whitney CG, Zaidi AK, Zell ER.

Vaccine. 2017 Jun 5;35(25):3295-3302. doi: 10.1016/j.vaccine.2017.04.037. Epub 2017 Apr 22. Review.

2.

Case-control vaccine effectiveness studies: Data collection, analysis and reporting results.

Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, Feikin DR, Groome MJ, Hajjeh RA, Johnson HL, Madhi SA, Mulholland K, O'Brien KL, Parashar UD, Patel MM, Rodrigues LC, Santosham M, Scott JA, Smith PG, Sommerfelt H, Tate JE, Victor JC, Whitney CG, Zaidi AK, Zell ER.

Vaccine. 2017 Jun 5;35(25):3303-3308. doi: 10.1016/j.vaccine.2017.04.035. Epub 2017 Apr 23. Review.

3.

Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.

Cohen C, von Mollendorf C, de Gouveia L, Lengana S, Meiring S, Quan V, Nguweneza A, Moore DP, Reubenson G, Moshe M, Madhi SA, Eley B, Hallbauer U, Finlayson H, Varughese S, O'Brien KL, Zell ER, Klugman KP, Whitney CG, von Gottberg A; South African IPD Case-Control Study Group.

Lancet Glob Health. 2017 Mar;5(3):e359-e369. doi: 10.1016/S2214-109X(17)30043-8. Epub 2017 Jan 28.

4.

Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine.

Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE; Active Bacterial Core Surveillance (ABCs) Team and MeningNet Surveillance Partners.

Pediatrics. 2017 Feb;139(2). pii: e20162193. doi: 10.1542/peds.2016-2193.

5.

Risk Factors for Presumed Bacterial Pneumonia Among HIV-uninfected Children Hospitalized in Soweto, South Africa.

Verani JR, Groome MJ, Zar HJ, Zell ER, Kapongo CN, Nzenze SA, Mulligan C, Moore DP, Whitney CG, Madhi SA.

Pediatr Infect Dis J. 2016 Nov;35(11):1169-1174.

PMID:
27276181
6.

Temporal Association of Rotavirus Vaccine Introduction and Reduction in All-Cause Childhood Diarrheal Hospitalizations in South Africa.

Groome MJ, Zell ER, Solomon F, Nzenze S, Parashar UD, Izu A, Madhi SA.

Clin Infect Dis. 2016 May 1;62 Suppl 2:S188-95. doi: 10.1093/cid/civ1204.

PMID:
27059355
7.

Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants.

Dangor Z, Kwatra G, Izu A, Adrian P, Cutland CL, Velaphi S, Ballot D, Reubenson G, Zell ER, Lala SG, Madhi SA.

Vaccine. 2015 Nov 27;33(48):6793-9. doi: 10.1016/j.vaccine.2015.10.019. Epub 2015 Oct 23.

PMID:
26478200
8.

Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants.

Dangor Z, Kwatra G, Izu A, Adrian P, Cutland CL, Velaphi S, Ballot D, Reubenson G, Zell ER, Lala SG, Madhi SA.

Expert Rev Vaccines. 2015;14(12):1651-60. doi: 10.1586/14760584.2015.1085307. Epub 2015 Sep 12.

PMID:
26364978
9.

Self-administration of intranasal influenza vaccine: Immunogenicity and volunteer acceptance.

Burgess TH, Murray CK, Bavaro MF, Landrum ML, O'Bryan TA, Rosas JG, Cammarata SM, Martin NJ, Ewing D, Raviprakash K, Mor D, Zell ER, Wilkins KJ, Millar EV.

Vaccine. 2015 Jul 31;33(32):3894-9. doi: 10.1016/j.vaccine.2015.06.061. Epub 2015 Jun 25.

10.

Effectiveness of pneumococcal conjugate vaccine against presumed bacterial pneumonia hospitalisation in HIV-uninfected South African children: a case-control study.

Madhi SA, Groome MJ, Zar HJ, Kapongo CN, Mulligan C, Nzenze S, Moore DP, Zell ER, Whitney CG, Verani JR.

Thorax. 2015 Dec;70(12):1149-55. doi: 10.1136/thoraxjnl-2014-206593. Epub 2015 Jun 19.

PMID:
26092924
11.

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH Jr, Pondo T, Rodgers L, McGee L, Beall B, Jorgensen JH, Whitney CG.

Lancet Infect Dis. 2015 Mar;15(3):301-9. doi: 10.1016/S1473-3099(14)71081-3. Epub 2015 Feb 3.

12.

Effects of vaccination on invasive pneumococcal disease in South Africa.

von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, Madhi SA, Zell ER, Verani JR, O'Brien KL, Whitney CG, Klugman KP, Cohen C; GERMS-SA Investigators.

N Engl J Med. 2014 Nov 13;371(20):1889-99. doi: 10.1056/NEJMoa1401914. Epub 2014 Nov 11.

13.

Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study.

Groome MJ, Page N, Cortese MM, Moyes J, Zar HJ, Kapongo CN, Mulligan C, Diedericks R, Cohen C, Fleming JA, Seheri M, Mphahlele J, Walaza S, Kahn K, Chhagan M, Steele AD, Parashar UD, Zell ER, Madhi SA.

Lancet Infect Dis. 2014 Nov;14(11):1096-1104. doi: 10.1016/S1473-3099(14)70940-5. Epub 2014 Oct 7. Erratum in: Lancet Infect Dis. 2014 Nov;14(11):1040.

PMID:
25303843
14.

Risk factors for invasive pneumococcal disease among children less than 5 years of age in a high HIV prevalence setting, South Africa, 2010 to 2012.

von Mollendorf C, Cohen C, de Gouveia L, Naidoo N, Meiring S, Quan V, Lindani S, Moore DP, Reubenson G, Moshe M, Eley B, Hallbauer UM, Finlayson H, Madhi SA, Conklin L, Zell ER, Klugman KP, Whitney CG, von Gottberg A; South African IPD Case–Control Study Group.

Pediatr Infect Dis J. 2015 Jan;34(1):27-34. doi: 10.1097/INF.0000000000000484.

PMID:
24992122
15.

Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study.

Cohen C, von Mollendorf C, de Gouveia L, Naidoo N, Meiring S, Quan V, Nokeri V, Fortuin-de Smit M, Malope-Kgokong B, Moore D, Reubenson G, Moshe M, Madhi SA, Eley B, Hallbauer U, Kularatne R, Conklin L, O'Brien KL, Zell ER, Klugman K, Whitney CG, von Gottberg A; South African Invasive Pneumococcal Disease Case-Control Study Group.

Clin Infect Dis. 2014 Sep 15;59(6):808-18. doi: 10.1093/cid/ciu431. Epub 2014 Jun 9.

16.

Racial disparities in invasive Streptococcus pneumoniae infections, 1998-2009.

Wortham JM, Zell ER, Pondo T, Harrison LH, Schaffner W, Lynfield R, Thomas A, Reingold A, Bennett NM, Petit S, Aragon D, Bareta J, Juni BA, Farley MM, Beall B, Moore MR.

Clin Infect Dis. 2014 May;58(9):1250-7. doi: 10.1093/cid/ciu108. Epub 2014 Feb 27.

PMID:
24585565
17.

Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease.

Fairlie T, Zell ER, Schrag S.

Obstet Gynecol. 2013 Mar;121(3):570-7. doi: 10.1097/AOG.0b013e318280d4f6.

PMID:
23635620
18.

Sentinel versus population-based surveillance of pneumococcal conjugate vaccine effectiveness.

Hampton LM, Zell ER, Schrag S, Cohen AL.

Bull World Health Organ. 2012 Aug 1;90(8):568-77. doi: 10.2471/BLT.11.098178. Epub 2012 May 11.

19.

Maternal HIV infection and vertical transmission of pathogenic bacteria.

Cutland CL, Schrag SJ, Zell ER, Kuwanda L, Buchmann E, Velaphi SC, Groome MJ, Adrian PV, Madhi SA; PoPS trial team.

Pediatrics. 2012 Sep;130(3):e581-90. Epub 2012 Aug 6.

PMID:
22869824
20.

Risk factors for neonatal sepsis and perinatal death among infants enrolled in the prevention of perinatal sepsis trial, Soweto, South Africa.

Schrag SJ, Cutland CL, Zell ER, Kuwanda L, Buchmann EJ, Velaphi SC, Groome MJ, Madhi SA; PoPS Trial Team.

Pediatr Infect Dis J. 2012 Aug;31(8):821-6. doi: 10.1097/INF.0b013e31825c4b5a.

PMID:
22565291
21.

Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines.

Hampton LM, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison LH, Lynfield R, Bennett NM, Petit S, Gershman K, Baumbach J, Beall B, Jorgensen J, Glennen A, Zell ER, Moore M.

J Infect Dis. 2012 Feb 1;205(3):401-11. doi: 10.1093/infdis/jir755. Epub 2011 Dec 7.

PMID:
22158567
22.

Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008.

MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, Gershman K, Harrison LH, Lynfield R, Petit S, Reingold A, Schaffner W, Thomas A, Coronado F, Zell ER, Mayer LW, Clark TA, Messonnier NE.

Clin Infect Dis. 2011 Dec;53(12):1230-6. doi: 10.1093/cid/cir735.

PMID:
22080119
23.

Measles elimination in the Americas: a comparison between countries with a one-dose and two-dose routine vaccination schedule.

Sever AE, Rainey JJ, Zell ER, Hennessey K, Uzicanin A, Castillo-Solórzano C, Dietz V.

J Infect Dis. 2011 Sep 1;204 Suppl 2:S748-55. doi: 10.1093/infdis/jir445.

PMID:
21954277
24.

[Propensity score methods for creating covariate balance in observational studies].

Pattanayak CW, Rubin DB, Zell ER.

Rev Esp Cardiol. 2011 Oct;64(10):897-903. doi: 10.1016/j.recesp.2011.06.008. Epub 2011 Aug 27. Review. Spanish.

25.

Incidence and severity of invasive Streptococcus pneumoniae, group A Streptococcus, and group B Streptococcus infections among pregnant and postpartum women.

Deutscher M, Lewis M, Zell ER, Taylor TH Jr, Van Beneden C, Schrag S; Active Bacterial Core Surveillance Team.

Clin Infect Dis. 2011 Jul 15;53(2):114-23. doi: 10.1093/cid/cir325.

PMID:
21690617
26.

Bacterial meningitis in the United States, 1998-2007.

Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold A, Bennett NM, Craig AS, Schaffner W, Thomas A, Lewis MM, Scallan E, Schuchat A; Emerging Infections Programs Network.

N Engl J Med. 2011 May 26;364(21):2016-25. doi: 10.1056/NEJMoa1005384.

27.

Healthcare utilization and cost of pneumococcal disease in the United States.

Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP, Finkelstein JA.

Vaccine. 2011 Apr 18;29(18):3398-412. doi: 10.1016/j.vaccine.2011.02.088. Epub 2011 Mar 11.

28.

Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.

Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners.

Pediatr Infect Dis J. 2011 Jun;30(6):451-5. doi: 10.1097/INF.0b013e31820a8b3c.

PMID:
21206392
29.

Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use.

Pilishvili T, Zell ER, Farley MM, Schaffner W, Lynfield R, Nyquist AC, Vazquez M, Bennett NM, Reingold A, Thomas A, Jackson D, Schuchat A, Whitney CG.

Pediatrics. 2010 Jul;126(1):e9-17. doi: 10.1542/peds.2009-2150. Epub 2010 Jun 14.

PMID:
20547641
30.

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.

Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE.

Clin Infect Dis. 2010 Jan 15;50(2):184-91. doi: 10.1086/649209.

PMID:
20001736
31.

Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial.

Cutland CL, Madhi SA, Zell ER, Kuwanda L, Laque M, Groome M, Gorwitz R, Thigpen MC, Patel R, Velaphi SC, Adrian P, Klugman K, Schuchat A, Schrag SJ; PoPS Trial Team.

Lancet. 2009 Dec 5;374(9705):1909-16. doi: 10.1016/S0140-6736(09)61339-8. Epub 2009 Oct 19.

PMID:
19846212
32.

Nasopharyngeal carriage of Streptococcus pneumoniae in Navajo and White Mountain Apache children before the introduction of pneumococcal conjugate vaccine.

Millar EV, O'Brien KL, Zell ER, Bronsdon MA, Reid R, Santosham M.

Pediatr Infect Dis J. 2009 Aug;28(8):711-6. doi: 10.1097/INF.0b013e3181a06303.

PMID:
19593248
33.

Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States.

Lucero CA, Hageman J, Zell ER, Bulens S, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Fridkin SK; Active Bacterial Core surveillance MRSA Investigators.

Vaccine. 2009 Aug 13;27(37):5061-8. doi: 10.1016/j.vaccine.2009.06.055. Epub 2009 Jul 2.

PMID:
19576943
34.

Evaluation of universal antenatal screening for group B streptococcus.

Van Dyke MK, Phares CR, Lynfield R, Thomas AR, Arnold KE, Craig AS, Mohle-Boetani J, Gershman K, Schaffner W, Petit S, Zansky SM, Morin CA, Spina NL, Wymore K, Harrison LH, Shutt KA, Bareta J, Bulens SN, Zell ER, Schuchat A, Schrag SJ.

N Engl J Med. 2009 Jun 18;360(25):2626-36. doi: 10.1056/NEJMoa0806820.

35.

Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007.

Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, Harrison LH, Lynfield R, Mohle-Boetani J, Zansky S, Albanese BA, Stefonek K, Zell ER, Jackson D, Thompson T, Schrag SJ.

Clin Infect Dis. 2009 Jul 1;49(1):85-92. doi: 10.1086/599369.

PMID:
19480572
36.

Assessing the sensitivity of surveillance for pneumonia in rural Thailand.

Chamany S, Burapat C, Wannachaiwong Y, Limpakarnjanarat K, Premsri N, Zell ER, Dowell SF, Feikin DR, Olsen SJ.

Southeast Asian J Trop Med Public Health. 2008 May;39(3):549-56.

PMID:
18564697
37.

Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005.

Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, Craig AS, Schaffner W, Zansky SM, Gershman K, Stefonek KR, Albanese BA, Zell ER, Schuchat A, Schrag SJ; Active Bacterial Core surveillance/Emerging Infections Program Network.

JAMA. 2008 May 7;299(17):2056-65. doi: 10.1001/jama.299.17.2056.

PMID:
18460666
38.

Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial.

O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R, Becenti J, Kvamme S, Whitney CG, Santosham M.

J Infect Dis. 2007 Oct 15;196(8):1211-20. Epub 2007 Sep 17.

PMID:
17955440
39.

Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators.

JAMA. 2007 Oct 17;298(15):1763-71.

PMID:
17940231
40.

Risk factors for invasive pneumococcal disease among Navajo adults.

Watt JP, O'Brien KL, Benin AL, McCoy SI, Donaldson CM, Reid R, Schuchat A, Zell ER, Hochman M, Santosham M, Whitney CG.

Am J Epidemiol. 2007 Nov 1;166(9):1080-7. Epub 2007 Aug 9.

PMID:
17693393
41.

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.

Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A.

Lancet. 2006 Oct 28;368(9546):1495-502.

PMID:
17071283
42.

Delivering pneumococcal vaccine to a high risk population: the Navajo experience.

Benin AL, Watt JP, O'Brien KL, Reid R, Zell ER, Katz S, Donaldson C, Schuchat A, Santosham M, Whitney CG.

Hum Vaccin. 2005 Mar-Apr;1(2):66-9. Epub 2005 Mar 25.

PMID:
17038821
43.

Adults with invasive pneumococcal disease: missed opportunities for vaccination.

Kyaw MH, Greene CM, Schaffner W, Ray SM, Shapiro M, Barrett NL, Gershman K, Craig AS, Roberson A, Zell ER, Schuchat A, Bennett NM, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.

Am J Prev Med. 2006 Oct;31(4):286-92. Epub 2006 Aug 22.

PMID:
16979452
44.

Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003.

Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili T, Roberson A, Zell ER, Whitney CG, Bennett NM; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.

Clin Infect Dis. 2006 Jul 15;43(2):141-50. Epub 2006 Jun 9.

PMID:
16779739
45.

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.

Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core Surveillance of the Emerging Infections Program Network.

N Engl J Med. 2006 Apr 6;354(14):1455-63. Erratum in: N Engl J Med. 2006 Aug 10;355(6):638.

46.

Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination.

Barzilay EJ, O'Brien KL, Kwok YS, Hoekstra RM, Zell ER, Reid R, Santosham M, Whitney CG, Feikin DR.

Vaccine. 2006 Feb 13;24(7):904-13. Epub 2005 Sep 12.

PMID:
16203059
47.

Increased prevalence of pediatric pneumococcal serotypes in elderly adults.

Feikin DR, Klugman KP, Facklam RR, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core surveillance/Emerging Infections Program Network.

Clin Infect Dis. 2005 Aug 15;41(4):481-7. Epub 2005 Jul 11.

PMID:
16028155
48.

The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults.

Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.

J Infect Dis. 2005 Aug 1;192(3):377-86. Epub 2005 Jun 23.

PMID:
15995950
49.

Assessing and monitoring vaccination coverage levels: lessons from the Americas.

Dietz V, Venczel L, Izurieta H, Stroh G, Zell ER, Monterroso E, Tambini G.

Rev Panam Salud Publica. 2004 Dec;16(6):432-42. Review. No abstract available.

PMID:
15673487
50.

Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections.

Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, Cieslak PR, Hadler J, Farley MM, Facklam RR, Zell ER, Whitney CG; Active Bacterial Core Surveillance/Emerging Infections Program Network.

JAMA. 2004 May 12;291(18):2197-203.

PMID:
15138241

Supplemental Content

Support Center